{
    "id": 4368,
    "fullName": "PTEN R130G",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "PTEN R130G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R130G confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 11051241, PMID: 10866302) and increased transformation ability in two different cell lines, as compared to wild-type Pten (PMID: 29533785).",
            "references": [
                {
                    "id": 2322,
                    "pubMedId": 11051241,
                    "title": "Functional evaluation of p53 and PTEN gene mutations in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11051241"
                },
                {
                    "id": 2304,
                    "pubMedId": 10866302,
                    "title": "Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10866302"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5728,
        "geneSymbol": "PTEN",
        "terms": [
            "PTEN",
            "10q23del",
            "BZS",
            "CWS1",
            "DEC",
            "GLM2",
            "MHAM",
            "MMAC1",
            "PTEN1",
            "PTENbeta",
            "TEP1"
        ]
    },
    "variant": "R130G",
    "createDate": "04/02/2015",
    "updateDate": "05/01/2018",
    "referenceTranscriptCoordinates": {
        "id": 169558,
        "transcript": "NM_000314",
        "gDna": "chr10:g.87933147C>G",
        "cDna": "c.388C>G",
        "protein": "p.R130G",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9373,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).",
            "molecularProfile": {
                "id": 26839,
                "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7135,
                    "pubMedId": 26232337,
                    "title": "Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26232337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9374,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",
            "molecularProfile": {
                "id": 26839,
                "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7135,
                    "pubMedId": 26232337,
                    "title": "Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26232337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9375,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",
            "molecularProfile": {
                "id": 26839,
                "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7135,
                    "pubMedId": 26232337,
                    "title": "Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26232337"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10283,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to Miransertib (ARQ092), demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 27339,
                "profileName": "PIK3CA R93W PIK3CA D350G PTEN R130G"
            },
            "therapy": {
                "id": 635,
                "therapyName": "Miransertib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4173,
            "profileName": "PTEN R130G",
            "profileTreatmentApproaches": [
                {
                    "id": 12957,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PTEN R130G"
                },
                {
                    "id": 12955,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PTEN R130G"
                },
                {
                    "id": 12956,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PTEN R130G"
                },
                {
                    "id": 12953,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PTEN R130G"
                },
                {
                    "id": 12954,
                    "name": "PIK3CB inhibitor",
                    "profileName": "PTEN R130G"
                }
            ]
        },
        {
            "id": 26839,
            "profileName": "KRAS G12D PIK3CA H1047R PTEN R130G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27339,
            "profileName": "PIK3CA R93W PIK3CA D350G PTEN R130G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 169558,
            "transcript": "NM_000314",
            "gDna": "chr10:g.87933147C>G",
            "cDna": "c.388C>G",
            "protein": "p.R130G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}